Business
Crescita Announces Filing of New Medical Device License
Crescita Announces Filing of New Medical Device License Canada NewsWire ...
About this update from Crescita Therapeutics, Inc.
[{"type":"text","content":"\n \n \n \n Crescita Announces Filing of New Medical Device License\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n.prnsblb0{\nBORDER-LEFT:black 0pt\n}\n.prnpl6{\nPADDING-LEFT:0.50em\n}\n.prnsbt0{\nBORDER-TOP:0pt\n}\n.prnpr6{\nPADDING-RIGHT:0.50em\n}\n.prnvab{\nVERTICAL-ALIGN: BOTTOM\n}\n.prnrbrb0{\nBORDER-RIGHT:black 0pt\n}\n.prnbcc{\nBORDER-COLLAPSE: COLLAPSE\n}\n.prnsbl0{\nBORDER-LEFT:0pt\n}\n.prnsbtb0{\nBORDER-TOP:black 0pt\n}\n.prnsbb0{\nBORDER-BOTTOM:0pt\n}\n.prnsbr0{\nBORDER-RIGHT:0pt\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n Laboratoires FILLMED files for Health Canada Approval of\n \n \n ART-FILLER\n \n ®\n \n Injectables in\n \n Canada\n \n \n \n \n \n LAVAL, QC\n \n ,\n \n Jan. 21, 2021\n \n /CNW Telbec/ - Crescita Therapeutics Inc. (TSX: CTX) and (OTC US: CRRTF) (\"Crescita\" or the \"Company\"), a commercial dermatology, today announced that Laboratoires FILLMED (\"FILLMED\") has submitted a New Medical Device License (\"MDL\") application for the ART FILLER\n \n ®\n \n range of products.\n \n \n \n \n \n \n \n \n \n Crescita and FILLMED entered into an agreement in\n \n January 2020\n \n , granting Crescita the exclusive rights to distribute the ART-FILLER injectables product range and the New Cellular Treatment Factor\n \n ®\n \n (\"NCTF\n \n ®\n \n \") in\n \n Canada\n \n . The ART FILLER is an exclusive collection of five hyaluronic acid (\"HA\")-based fillers. Since it was developed in 2016, healthcare professionals including dermatologists and plastic surgeons outside\n \n Canada\n \n have used it to create or restore the volumes and contours of the face, to temporarily eliminate superficial-to-deep wrinkles and facial folds, and to augment and volumize the lips.\n \n \n The ART-FILLER range of products were submitted for approval by Health Canada as Class III medical devices. Due to backlogs created by the COVID-19 pandemic, it is estimated that the average target review time for a Class III MDL application may take as long as 6-9 months.\n \n \n In 2018, the dermal fille...